Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$51.61

-0.03 (-0.06%)

07:11
11/06/18
11/06
07:11
11/06/18
07:11

Ionis Pharmaceuticals reports Q3 EPS (3c), consensus (16c)

Reports Q3 revenue $145M, consensus $152.68M.

  • 06

    Nov

  • 27

    Nov

IONS Ionis Pharmaceuticals
$51.61

-0.03 (-0.06%)

10/03/18
MSCO
10/03/18
NO CHANGE
Target $45
MSCO
Equal Weight
Ionis most likely gets Tegsedi approval with black box, says Morgan Stanley
Morgan Stanley analyst David Lebowitz laid out three potential scenarios for the upcoming FDA approval decision about Ionis Pharmaceuticals' Tegsedi, which is scheduled to come on or before October 6. If the FDA were to issue a complete response letter, or CRL, and prevent on-time launch, Lebowitz sees greater than 20% downside for the shares, though he puts the probability of this occurring at 40%. If Tegsedi is approved with a black box safety warning, which he sees as the most likely scenario with odds he pegs at 45%, Lebowitz sees the stock trading up or down about 5%. If Tegsedi is approved with a "clean" label it would lead to a steeper ramp in revenue and Lebowitz sees 20% or more upside to the stock in this scenario, though he puts the odds at just 15%. He maintains an Equal Weight rating on Ionis shares ahead of the PDUFA with a $45 price target.
10/07/18
PIPR
10/07/18
NO CHANGE
Target $160
PIPR
Overweight
Alnylam's Onpattro highly efficacious, safer than competitor, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Ionis Pharmaceuticals (IONS) announced FDA approval of TEGSEDI for treatment of hATTR polyneuropathy. The analyst also points out that the label includes a Black Box warning for thrombocytopenia and glomerulonephritis requiring every 2-week monitoring, and will be marketed by Ionis subsidiary Akcea (AKCA) with a Risk Evaluation and Mitigation Strategy. TEGSEDI is administered subcutaneously every week versus Alnylam's (ANLY) ONPATTRO intravenously every 3 weeks with steroids, he adds. Tenthoff believes that ONPATTRO appears safer and highly efficacious, and should win out. The analyst reiterates an Overweight rating and $160 price target on Alnylam shares.
10/08/18
CANT
10/08/18
INITIATION
Target $135
CANT
Overweight
Cantor reiterates Overweight on Alnylam after Akcea, Ionis win approval
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on Alnylam Pharmaceuticals (ALNY) with a $135 price target after the FDA approved Tegsedi, to be marketed by Akcea Therapeutics (AKCA). The analyst says that while the approval introduces another competitor to the market, she still expects Alnylam's Onpattroto be able to take significant share in the polyneuropathy hATTR market. Young thinks the Tegsedi label is more onerous and currently models a 60% peak share to Alnylam, a 25% share to Tegsedi and 15% to future competition.
10/08/18
GSCO
10/08/18
NO CHANGE
Target $36
GSCO
Sell
Ionis' Tegsedi to face commercial headwinds, says Goldman Sachs
After the FDA approved Ionis (IONS) and affiliate Akcea Therapeutics' (AKCA) Tegsedi for adult polyneuropathy of hereditary transthyretin-mediated amyloidosis, but with a black box warning, Goldman Sachs analyst Salveen Richter said he believes the drug faces commercial headwinds. He cites the underlying safety profile and requirement for consistent monitoring as well as the recent launch of Alnylam's (ALNY) Onpattro and expected launch of Pfizer's (PFE) tafamidis in the first half of 2019. Richter keeps a Sell rating on Ionis shares with a price target of $36.

TODAY'S FREE FLY STORIES

ALK

Alaska Air

$67.68

0.29 (0.43%)

06:23
11/19/18
11/19
06:23
11/19/18
06:23
Initiation
Alaska Air initiated  »

Alaska Air initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

GE

General Electric

$8.04

-0.135 (-1.65%)

, SIEGY

Siemens

$0.00

(0.00%)

06:21
11/19/18
11/19
06:21
11/19/18
06:21
Periodicals
GE chases power sales in Iraq as report highlights corruption concerns, WSJ says »

General Electric (GE) has…

GE

General Electric

$8.04

-0.135 (-1.65%)

SIEGY

Siemens

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPX

GP Strategies

$14.14

-0.03 (-0.21%)

06:20
11/19/18
11/19
06:20
11/19/18
06:20
Hot Stocks
GP Strategies awarded multi-year contract extension from banking organization »

GP Strategies announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCHW

Charles Schwab

$46.97

-0.35 (-0.74%)

, AMTD

TD Ameritrade

$52.32

-0.28 (-0.53%)

06:20
11/19/18
11/19
06:20
11/19/18
06:20
Downgrade
Charles Schwab, TD Ameritrade rating change  »

Charles Schwab downgraded…

SCHW

Charles Schwab

$46.97

-0.35 (-0.74%)

AMTD

TD Ameritrade

$52.32

-0.28 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GHG

GreenTree Hospitality

$12.53

0.01 (0.08%)

06:18
11/19/18
11/19
06:18
11/19/18
06:18
Earnings
Breaking Earnings news story on GreenTree Hospitality »

GreenTree Hospitality…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

AMTD

TD Ameritrade

$52.32

-0.28 (-0.53%)

06:17
11/19/18
11/19
06:17
11/19/18
06:17
Upgrade
TD Ameritrade rating change  »

TD Ameritrade upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GHG

GreenTree Hospitality

$12.53

0.01 (0.08%)

06:16
11/19/18
11/19
06:16
11/19/18
06:16
Earnings
GreenTree Hospitality reports Q3 core EPS 18c , two estimates 19c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

CTSH

Cognizant

$70.10

1.63 (2.38%)

06:15
11/19/18
11/19
06:15
11/19/18
06:15
Recommendations
Cognizant analyst commentary  »

Confidence in Cognizant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 02

    Dec

  • 04

    Dec

06:15
11/19/18
11/19
06:15
11/19/18
06:15
General news
Risk aversion picks up on reports that Renault-Nissan Ghosn has been arrested. »

Risk aversion picks up on…

YETI

Yeti

$16.99

0.1 (0.59%)

06:13
11/19/18
11/19
06:13
11/19/18
06:13
Initiation
Yeti initiated  »

Yeti initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

TSLA

Tesla

$354.46

6.09 (1.75%)

06:12
11/19/18
11/19
06:12
11/19/18
06:12
Conference/Events
Tesla management to meet with RBC Capital »

Group luncheon with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 27

    Nov

  • 13

    Dec

HP

Helmerich & Payne

$62.59

2.54 (4.23%)

06:12
11/19/18
11/19
06:12
11/19/18
06:12
Upgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTI

W&T Offshore

$6.13

0.02 (0.33%)

06:11
11/19/18
11/19
06:11
11/19/18
06:11
Conference/Events
W&T Offshore management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

EV

Eaton Vance

$42.62

-0.435 (-1.01%)

06:11
11/19/18
11/19
06:11
11/19/18
06:11
Downgrade
Eaton Vance rating change  »

Eaton Vance downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TPR

Tapestry

$40.63

-0.36 (-0.88%)

06:10
11/19/18
11/19
06:10
11/19/18
06:10
Conference/Events
Tapestry management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

TPR

Tapestry

$40.63

-0.36 (-0.88%)

06:10
11/19/18
11/19
06:10
11/19/18
06:10
Conference/Events
Tapestry management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

USB

U.S. Bancorp

$54.93

0.26 (0.48%)

06:10
11/19/18
11/19
06:10
11/19/18
06:10
Recommendations
U.S. Bancorp analyst commentary  »

U.S. Bancorp positioned…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TELL

Tellurian

$8.03

0.11 (1.39%)

06:10
11/19/18
11/19
06:10
11/19/18
06:10
Conference/Events
Tellurian management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

CRM

Salesforce

$132.59

0.09 (0.07%)

06:09
11/19/18
11/19
06:09
11/19/18
06:09
Periodicals
Salesforce CEO defends contract with Customs and Border Patrol, Recode reports »

Salesforce CEO Marc…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 27

    Nov

  • 27

    Nov

  • 28

    Nov

  • 29

    Nov

  • 06

    Dec

  • 11

    Dec

  • 03

    Mar

OSK

Oshkosh

$66.91

-0.46 (-0.68%)

06:09
11/19/18
11/19
06:09
11/19/18
06:09
Conference/Events
Oshkosh management to meet with Buckingham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 04

    Dec

  • 05

    Dec

VICI

VICI Properties

$21.29

0.16 (0.76%)

06:09
11/19/18
11/19
06:09
11/19/18
06:09
Initiation
VICI Properties initiated  »

VICI Properties initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

CARG

CarGurus

$38.76

0.31 (0.81%)

06:08
11/19/18
11/19
06:08
11/19/18
06:08
Initiation
CarGurus initiated  »

CarGurus initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

KOP

Koppers Holdings

$20.18

-1.315 (-6.12%)

06:08
11/19/18
11/19
06:08
11/19/18
06:08
Conference/Events
Koppers Holdings management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 26

    Nov

  • 27

    Nov

CMRE

Costamare

$5.35

0.01 (0.19%)

06:07
11/19/18
11/19
06:07
11/19/18
06:07
Hot Stocks
Costamare acquires 60% equity interest in five 14,000 TEU containerships »

Costamare announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INXN

Interxion

$64.10

0.62 (0.98%)

06:07
11/19/18
11/19
06:07
11/19/18
06:07
Conference/Events
Interxion management to meet with SunTrust »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.